Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Pyxis is focused on developing next-generation therapies to target difficult-to-treat cancers, with a broad portfolio of novel antibody drug conjugate (ADC) candidates and monoclonal antibody (mAb) preclinical discovery programs. It is developing its ADC candidates and mAb preclinical discovery programs for difficult-to-treat solid and hematologic tumors. Pyxis anticipates submitting INDs for two of its ADC candidates by mid-2022, and another candidate by 2023.
The Cambridge, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol PYXO (10/4/21 update: PYXS). Pyxis Oncology filed confidentially on June 21, 2021. BofA Securities, Jefferies, Credit Suisse, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
